Sign up to receive product information and helpful resources and tools.

First Name required
LastName required
Email Address required Invalid email
Zip code required

Intended for US residents only. Mylan Pharmaceuticals, a VIATRIS Company understands that your personal and health information is private. The information you provide will only be used by Mylan Pharmaceuticals, a Viatris Company and parties acting on its behalf to send you the materials you requested and other helpful information and updates on XULANE, as well as related treatments, products, offers and service. You may remove yourself from this mailing list at any time by clicking "unsubscribe" on any e-newsletters or other communications that you receive. To learn about how Viatris uses your information, please view our Privacy Statement.


What is the Pearl Index of XULANE transdermal patch?

In clinical trials, NGMN/EE transdermal patch had a Pearl Index of 1.07 (95% CI, 0.60, 1.76)*, and is 99% effective2† when used as directed.

The pregnancy rate in women aged 18 to 35 years was 1.07 (95% CI 0.60, 1.76) per 100 woman-years. To achieve maximum contraceptive effectiveness, XULANE must be used exactly as directed. XULANE must adhere securely to the skin to work properly. See Limitations of Use.

*Differences exist from inclusion criteria from the more recent FDA Draft Guidance on calculations of Pearl Index. The impact on Pearl Index may be minimal. †In 3 large clinical trials lasting 12 months, 3,330 women (ages 18 to 45) completed 2,155 cycles of NGMN/EE (Ortho Evra®) transdermal system use.

Patient talking to Doctor


  1. FDA. Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy – Guidance for Industry. Available from: Accessed April 22 2020.
  2. XULANE Prescribing Information. March 2022. Mylan Pharmaceuticals Inc. Morgantown, WV.